Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Return on Sales (2017 - 2026)

Lexaria Bioscience's Return on Sales history spans 10 years, with the latest figure at 72.64% for Q1 2026.

  • Quarterly results put Return on Sales at 72.64% for Q1 2026, down 5683.0% from a year ago — trailing twelve months through Feb 2026 was 25.72% (down 788.0% YoY), and the annual figure for FY2025 was 16.83%, down 447.0%.
  • Return on Sales for Q1 2026 was 72.64% at Lexaria Bioscience, down from 20.62% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 4.61% in Q1 2024 to a low of 406.6% in Q3 2022.
  • The 5-year median for Return on Sales is 21.55% (2025), against an average of 49.9%.
  • The sharpest move saw Return on Sales plummeted -40659bps in 2022, then soared 37036bps in 2023.
  • Year by year, Return on Sales stood at 17.35% in 2022, then surged by 57bps to 7.48% in 2023, then tumbled by -96bps to 14.63% in 2024, then plummeted by -41bps to 20.62% in 2025, then plummeted by -252bps to 72.64% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 72.64%, 20.62%, and 15.44% for Q1 2026, Q4 2025, and Q3 2025 respectively.